Skip to main content

Erasca, Inc Investor Event Transcript, Nov 10, 2026

Erasca, Inc. (ERAS)

ERAS plans three registration-enabling studies after raising $632 million in July, with pancreatic phase three initiation in 2027 and lung phase three starts between the second half of 27 and first half of 28. AI summary

Investor Event Transcript 2026-11-10 For: 2026-12-31
Added on November 15, 2026

Conference Transcript - ERAS 2026-11-10

David Chacko, CFO

I think we'll get started.

Paul Jang, Analyst — Guggenheim

So welcome to this next session. Our next presenting company is Araska. My name is Paul Jang. I'm one of the biotech analysts with Guggenheim. And I'm very pleased to be joined today by Jonathan Lim, Chairman and CEO, and David Chacko, CFO and CBO from Araska. Thanks for joining you guys.

Jonathan Lim, Chairman

Thanks, Paul. Great to be here. So maybe a good place to start is just to provide a quick intro to the company and your pipeline for those who might be newer to the story. Yeah, RASCA was formed in 2018 around the premise of erasing cancer and eradicating RAS-driven cancer. In fact, that mission is in our name. And we, since then, have built a pipeline. We've gone after the MAP kinase pathway broadly, but we've really settled on, you know, focusing entirely on RAS with a pipeline that we're very excited about. So we have ERAS15, a pan-RAS molecular glue that's focused on really targeting RAS broadly in terms of all the key mutations, including also RAS wild type in terms of K, H, and N. And then we also have ERAS-4001, which is a pan-KRAS small molecule inhibitor, so it's a switch-two pocket binder that spares H and NRAS but hits KRAS really hard. And so we're also excited about the prospect of putting those two molecules together, which I know we'll talk about later.

Paul Jang, Analyst — Guggenheim

Okay, great. So ERAS-15, your PAN-RAS inhibitor, had a couple updates this year, April and July, which were really interesting. So I was hoping you could first start by perhaps recapping the data that you showed, efficacy and safety profile, and then sort of looking forward, you will have some updates for the program at the upcoming triple meeting in November. So maybe set some expectations with that in the context of what you've already shown.

Jonathan Lim, Chairman

Yeah, so... We're really excited about ERAS-15 PanRAS program. Basically, what we've shown in April and July corporate disclosures is very compelling single-agent activity in both pancreatic cancer as well as non-small cell lung cancer, as well as safety and tolerability. And so as we look towards the triple meeting, we have an oral plenary presentation, and this is really geared towards more the scientific audience. For most clinicians, they're aware of our data, but I think there's some clinicians where when we've given corporate updates, those data may not be as visible as they would be in a scientific conference. So there's really a coming out, so to speak, for the scientific data. Now, what we've shown in the April and July disclosures is in pancreatic cancer, monotherapy activity, that's somewhere in the 40 to 57 percent response rate. And that really depends on line of treatment as well as dose. And so, you know, what we're hoping with the upcoming data disclosure is, first of all, more patients enrolled, especially at the what we call RDE, which are the recommended doses for expansion at 24 and 32 milligrams. So I think that that's something to pay attention to because in that July data set, we did see a pretty striking dose response. So we had higher response rates at the highest response rates were at 32 milligrams and the lowest response rates were at 16 and then 24 was somewhere, you know, in between. So I think we're going to want to pay attention to sort of the 32 milligram dose, especially, and then also 24 milligram, and then just see whether that response rate lands within that 40 to 57 percent range. I think we're going to want to see the line of treatment. We're also going to want to see the mutation breakout. I think there's an opportunity, especially for G12D, to show, you know, an opportunity for improvement over what's been reported for the comparator, where, you know, in FDA documents, it looked like the response rate was 24% against G12D. So, I think in the July dataset, when you look at sort of what's been publicly disclosed, I think people have, you know, come to the conclusion that G12D... Along a dose range was somewhere in the 50% zip code. So as we show more data at the 24 and 32 milligram doses, are we sort of landing in that 50 plus percent range? And then in an all comers, if we're able to land somewhere in the, call it, you know, mid 40s or so, that still would be about 10 to 20 points differentiated versus what's been reported in the past with with response rates in the 25 to 32% range. So I think that's how we look at pancreatic is it's really exciting what's been achieved by, you know, directs on RACID in the second line setting. But I think there's an opportunity for better efficacy, as well as when you look at the safety and tolerability side of the equation. And I think, you know, interruptions and dose reductions have reported in the New England Journal paper have been quite high, you know, in that 36 to 56 percent range. So I think ultimately, we hope to be able to show improvements in the frequency and severity of rash, GI, and stomatitis, but ultimately, how do those translate into maintaining dose for patients to deliver the optimal dose to patients in a really aggressive tumor type like pancreatic? So if we're able to show meaningfully lower dose interruptions and reductions, we think that that's the other side of the equation that's really important. And then finally, for lung cancer, you know, what we've reported previously was response rates in the 60-plus percent range. If you look at the best targeted therapies in KRAS-G12X, you know, Diva-Rasiv is sort of an example of a very potent G12C molecule that has achieved response rates in the 56 to 59 percent range. I think if we hold at or above that threshold in a non-G12C space, which actually is less sensitive to target inhibition than G12C tumors, which tend to be a little more sensitive to targeted therapy, then we'll be feeling very good going into the pivotal trials next year in second line plus, as well as first line, that we have a very promising lung cancer drug. So... I think the totality of efficacy and safety in terms of what we've reported, we hope to have longer follow-up for these patients, hopefully more confirmed response rates than unconfirmed, and then I think if we sort of hold within those target ranges, then we'll really have a differentiated drug.

Paul Jang, Analyst — Guggenheim

Okay, yeah, super helpful. Any sense of, I guess, the scope of the data in terms of patient numbers we should expect?

Jonathan Lim, Chairman

Yeah, I think meaningfully higher. So I think especially because we've been putting our thumb on the scale. So just to back up, the PAD or pharmacologically active dose for ERAS-15 is 16 milligrams on the low end and then 32 milligrams on the high end. And it really has differed by indication. So I think in pancreatic cancer, which tends to be a little less sensitive to targeted therapy than lung cancer, we've seen more responses, more in that 24 to 32 milligram range, and that's why I think especially at 32 milligrams, you just want to put as much drug and get as much exposure as you can. Because from a PK standpoint, we do have dose proportional, we've reported dose proportional increases in exposure from 16 to 24 to 32. We don't have that exposure plateau that's been observed with other molecules within this class. So I think for pancreatic, that really matters. So I think we should have, you know, in the July data set, if we had 15 patients at 24 to 32, hopefully we have, you know, maybe more than twice that. And then with Lung cancer, 16 to 32, because it's a more sensitive tumor type, we actually had quite a lot of responses at 16 milligrams in the April data set. So I think now with more patients at 32, at that time, we only had one patient at 32 milligrams responding. And so I think now with more patients at 32, we'll see if there's more meaningful activity at those higher end of the range.

Paul Jang, Analyst — Guggenheim

Okay, super. So you talked a little bit about the focus indications in lung as well as PDAC and, you know, thinking about a pivotal study at this point. So I guess what does the sort of pathway look like in terms of getting that first study launched? How are you prioritizing lung versus PDAC and anything about possible timing for getting a study launched?

Jonathan Lim, Chairman

Yeah, so we're moving as fast as we can. So I think based on the data that we've disclosed, we already had the conviction that, you know, going into that, we weren't sure if there would be trade-offs of either better safety or better efficacy. But the fact that from April to July, we saw data that convinced ourselves that we were meaningfully better on both sides of that equation, we unlocked and were able to do a pretty significant financing so that we have the balance sheet to really unlock three pivotal trials, two of which are phase threes. So, you know, on pancreatic cancer, we have high conviction that first-line pancreatic, if we're able to see a difference in second-line plus and even third-line plus, so heavily pretreated population, then we think, you know, line of treatment does matter and we should see even better activity in the first-line setting. So we basically are doing all of the, you know, blocking and tackling in terms of all the operational activities that one would need to do to move into a phase three trial. And so we're on track, you know, our guidance has been 2027 in terms of starting that, and we're on track for that. And you can imagine we're moving as fast as we can. In non-small cell lung cancer, we're taking sort of a dual approach of going after second-line plus non-small cell, RAS mutant non-small cell lung cancer with monotherapy, and that potentially registration-enabling trial will start in the first half of next year. And then we are also looking at first-line combinations for first-line RAS-mutant lung, and so we've disclosed that we're combining with PEMBRO. We have a clinical trial collaboration with Merck, and so we are in dose escalation with PEMBRO. I'd say that if we go with a PEMBRO-only combo, we could start that phase three as early as the second half of next year. And then if we want to layer on chemo on top of that, then we would start that in the first half of 28. And so that's why we've broadbanded the guidance for that first-line trial for phase three between second half of 27 and first half of 28.

Paul Jang, Analyst — Guggenheim

Okay. So, you mentioned that, you know, the successes as well as possible liabilities of Dirac's and RASIB are really important in the way you think about the opportunity. So, yeah, just wanted to get your thoughts on, you know, how you are tracking the launch, the commercial opportunity that's being sort of shown by the asset, and how that informs, you know, how you think about your bar for success for 15.

Jonathan Lim, Chairman

Yeah, first of all, diraxone-rasib is just a great pioneer molecule, and we're super excited that patients now have access to that. And, you know, I think the first quarter of sales for five weeks was really phenomenal. So I think that's great that patients, you know, it's a very high unmet need. But as I said, I think there's, especially when you think about just monotherapy tolerability, and then when you combine it with chemo in that frontline setting, I just think that, you know, there's room for improvement, and there's room for more than one molecule. So we're excited to sort of build on that success of this class of molecules and really make sure that other treatment options are available for patients. So if you look at tolerability with chemo, you know, down-dosing has been necessary on both the pan-ras side as well as on the chemo side, you know, somewhere around 36 to 58 percent, depending on what side of the equation you're talking about. So I think we won't know until we actually have our chemo data, but as we dose escalate, can we reach 24 to 32 milligrams? And can we be able to sort of combine successfully with chemo with less down dosing? I think if we can, then that would also, I think, convert into potential patient benefit in terms of response rates, tolerability, durability, all of that good stuff.

Paul Jang, Analyst — Guggenheim

Um, and then on the mutant selective side, there's also a number of RAS-G12D selective agents that are now in phase three, including, uh, in frontline PDAC. So, so how does this impact, if at all, your evaluation on the landscape and opportunity, uh, in PDAC for RAS-15?

Jonathan Lim, Chairman

So we have a hypothesis on that, and I think if our hypothesis is true, then I think pan-ras is going to be an essential element of a frontline strategy for pancreatic cancer. And so the hypothesis is this. If you look at the allele-specific D inhibitors, whether they are a molecular glue or sort of a switch-to-pocket binder, the response rates that have been... Disclosed for the, or reported for those, are anywhere from 30 to 41 percent, with, you know, Zoldan-Rasib at 30 percent response rate, Veristem's molecule is about 41, and then Insights is in between at 37 percent. So, you know, we'll know more next week, but let's say that based on the publicly available data, which shows that at a dose range, our molecule achieved about 50% plus G12D response rate. Why is it that there seems to be a range bound? Nature of these allele specifics, but you're getting higher response rates with a pan-rass, and it probably has to do with wild-type signaling. So, if you take an allele-specific approach, by definition, you're sparing wild-type, and beyond that, you're actually sparing not just K, but also H and NRAS wild-type signaling, and you will need a pan-RAS to address that, both for primary and acquired resistance. So, we think that that hopefully translates into an ORR benefit, but more importantly, a durability benefit, and time will tell. So there's just a hypothesis at this point, but based on our early read of the data that are available by ourselves as well as others, we just think there's potentially something there.

Paul Jang, Analyst — Guggenheim

Okay. So this question might segue into a conversation about 4001, but you're also going to be presenting some data at triple for preclinical data with the 15 combo with 4001. So can you just speak about the rationale for combining PanRAS with PanKRAS and what we might expect from that data and any future development that would come out of it?

Jonathan Lim, Chairman

Yeah, so PanRAS works by two mechanisms. One is the steric clash to basically inhibit MAP kinase signaling. The second is increased hydrolysis of RAS from the GTP state to the RAS GDP or off state. And then when you take ERAS-15 to induce that off-state, and you take 4001, which is an off-state-preferring molecule, then you basically affect this one-two punch on tumors. So our poster presentation next week is really going to show the totality of data that we have for in vitro and in vivo, showing the possible synergy of that one-two punch. So, we're excited about that, and if that can translate in the clinic, then that could be really interesting as well.

Paul Jang, Analyst — Guggenheim

Okay, and then speaking of clinics, so, you know, you are going to have a clinical readout for 4001 from the Borealis I study in the near term. So, what do we expect from that upcoming update?

David Chacko, CFO

So the Borealis I study is our pan-KRAS inhibitor study. We have guided to the fact that we'll have a phase one dose escalation update in the second half of this year. And so it is what you would expect for a phase one dose escalation. So its focus will be on safety, tolerability, PK, initial signs of activity, and with a focus on, you know, dozens of patients. And that will be the nature of that update.

Paul Jang, Analyst — Guggenheim

Okay, and how do you think about, I guess, the, you know, the pan-KRAS opportunity in light of the other pan-KRAS and mutant selective inhibitors in development? You know, how do you differentiate the development of this asset compared to even ARAS-15?

David Chacko, CFO

Yeah, so there haven't been much in the way of data disclosures from other pan-KRAS inhibitors, just a couple of companies. And so how we think about it goes back to what Jonathan, you know, mentioned about the combination potential, for instance, with 0015. Because a pan-RAS inhibitor works through those two mechanisms that Jonathan was describing, including causing hydrolysis of RAS to the GDP state, this is where you have that potential for 4001 being more off-state preferring to be able to affect this 1-2 punch in combination with 0015. And so we are thinking about this in terms of its combination potential, and if it shows good results out of the dose escalation study, then that allows it to potentially be a combination partner for 0015 with that 1-2 punch against the RAS protein.

Paul Jang, Analyst — Guggenheim

Great. So, I guess, speaking of combos, there's a couple other interesting ones that I wanted to talk about. So, one is the PRMT5 combination. I think you recently initiated the combo with Tango's inhibitor. So, first, can you talk a little bit about the scientific rationale for combining PanRAS with PRMT5, the way you see it, and what you would expect for this combo in light of the landscape out there?

David Chacko, CFO

Yeah, so the rationale for it is what you would expect. I mean, these tumors are RAS-driven, and then also with an MTAP deletion that leads to dependence on PRMT5. And so if you are able to hit it with both a RAS inhibitor as well as a PRMT5 inhibitor, then you should see this dual inhibition of the tumor. And you see that in terms of the data that were presented a couple weeks ago at ESMO with an 82% response rate in the combination with PanRAS plus PRMT5. And we think that in our case, you know, we could potentially show differentiated results, especially if you end up combining with a differentiated pan-RAS molecule like ERAS-0015. And so we're very excited about this combination. We just issued a joint press release with Tango that we initiated the study of our molecule with Boki metastat. And so that's an exciting combination for us.

Paul Jang, Analyst — Guggenheim

Okay, great. And then on a different combination front, you also have a collaboration with Merck to evaluate 0015 with Pembro in solid tumors. So, yes, can you speak about what the focus of this may be on? Is it going to be lung or some other tumor types? And when might we expect some data from the cohort?

David Chacko, CFO

Yeah, we do have a supply agreement with Merck where, as Jonathan mentioned, they are supplying us with Pembro for our combination study with ERS-0015. That's also another exciting combination. You know, when you think about a pan-RAS inhibitor, it has so many different ways that you could think about combining, and it goes back to Jonathan's earlier point as well about the safety and tolerability being very important as you think about, you know, different combinations. In terms of where it could play, I mean, one of the most obvious areas is in lung cancer. And as Jonathan mentioned, we are looking at that combination of 0015 plus Pembro with or without chemotherapy, which would allow us to be, if we were able to do that, allow us to play in that first-line lung setting as the only pan-ras that would be able to play there or is playing there. And so that's an area that has been met with a lot of enthusiasm from the KOLs that we've spoken to as a potential mutation-agnostic opportunity in the first-line setting.

Paul Jang, Analyst — Guggenheim

All right, fantastic. So I think with that, maybe to close, can you talk about your cache runway and sort of what inflection points it gets you through?

David Chacko, CFO

Yeah, so we'll be reporting earnings later this week. So I'll give you our Q2 number, which was that we ended Q2 with $384 million of cash. That does not include the $632 million that we subsequently raised in July. So call it about a billion dollars on the balance sheet, plus or minus. In terms of the milestones, it covers all of the corporate milestones that we talked about, including initiating those three potential registration enabling studies, two in lung, one in PANQ.

Paul Jang, Analyst — Guggenheim

Okay, great. Thanks for the heads up on earnings, and I think with that, we'll close. I thank you guys so much for joining us. Thank you.